NeuroOne® Investor Call Replay Available Through April 11th

Rhea-AI Summary

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced a telephone replay of its investor conference call will be available until April 11, 2022. The call discussed the company's recent disclosures, including clarification on its 510(k) clearance request for the Evo® sEEG Electrode for short-term use. CEO Dave Rosa, along with biocompatibility expert Dr. William Wustenberg, addressed public questions during the call. The device is already cleared for use of less than 24 hours. For further details, visit www.n1mtc.com.

Positive

• Successful clarification of 510(k) clearance request for Evo® sEEG Electrode.
• Expert involvement from Dr. William Wustenberg enhances credibility.

Negative

• None.

EDEN PRAIRIE, Minn., March 30, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that a telephone replay of its investor conference call discussing recent disclosures, held yesterday, will be available through April 11, 2022. The webcast replay will be available for one year.

During the investor call, NeuroOne CEO Dave Rosa was joined by Dr. William Wustenberg, a biocompatibility expert that has worked with over 1500 companies over the past 25 years to provide guidance on biocompatibility testing required for a variety of FDA submissions. Mr. Rosa provided clarification regarding the disclosure included in the Company's Form 8-K filed March 25, 2022 about its 510(k) clearance request to the FDA for its Evo® sEEG Electrode for less than 30-day use while Mr. Rosa and Dr. Wustenberg also answered questions submitted by the public. The device has already been 510(k) cleared for temporary (less than 24 hours) use.

Telephone Replay
877-660-6853 / 201-612-7415
End Date: 2022-04-11
Access ID: 13728487

Webcast Replay 
https://services.choruscall.com/mediaframe/webcast.html?webcastid=TiuTgwf3

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com .

View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroone-investor-call-replay-available-through-april-11th-301513676.html

SOURCE NeuroOne Medical Technologies Corporation

FAQ

What was discussed in the NeuroOne conference call on March 30, 2022?

The call discussed the 510(k) clearance request for the Evo® sEEG Electrode and addressed public questions.

When is the telephone replay of the NeuroOne investor call available until?

The replay will be available until April 11, 2022.

Who participated in the NeuroOne investor conference call?

CEO Dave Rosa and biocompatibility expert Dr. William Wustenberg participated in the call.

What is the current clearance status of the Evo® sEEG Electrode?

The Evo® sEEG Electrode is cleared for temporary use of less than 24 hours and is seeking clearance for less than 30 days.

Where can I find more information about NeuroOne Medical Technologies Corporation?

More information can be found on their website at www.n1mtc.com.